Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Prescient Therapeutics Limited ( (AU:PTX) ) has shared an announcement.
Prescient Therapeutics Limited announced the cessation of 1,000,000 options, which expired without exercise on December 21, 2024. This cessation of securities is part of the company’s routine financial adjustments and reflects the dynamic nature of investment instruments in the biotechnology sector.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative cancer treatments. The company is known for its work on targeted therapies and personalized medicine aimed at improving cancer treatment outcomes.
YTD Price Performance: -4.00%
Average Trading Volume: 635,454
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$38.66M
For an in-depth examination of PTX stock, go to TipRanks’ Stock Analysis page.